250 related articles for article (PubMed ID: 15479756)
1. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.
Bongartz T; Coras B; Vogt T; Schölmerich J; Müller-Ladner U
Rheumatology (Oxford); 2005 Jan; 44(1):126-9. PubMed ID: 15479756
[TBL] [Abstract][Full Text] [Related]
2. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
3. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.
Mazzotta A; Esposito M; Schipani C; Chimenti S
J Dermatolog Treat; 2009; 20(6):354-8. PubMed ID: 19954392
[TBL] [Abstract][Full Text] [Related]
4. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA
Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
[TBL] [Abstract][Full Text] [Related]
5. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
[TBL] [Abstract][Full Text] [Related]
6. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
[TBL] [Abstract][Full Text] [Related]
7. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide in psoriatic arthritis.
Kaltwasser JP
Autoimmun Rev; 2007 Sep; 6(8):511-4. PubMed ID: 17854740
[TBL] [Abstract][Full Text] [Related]
9. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
11. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
Fraser AD; van Kuijk AW; Westhovens R; Karim Z; Wakefield R; Gerards AH; Landewé R; Steinfeld SD; Emery P; Dijkmans BA; Veale DJ
Ann Rheum Dis; 2005 Jun; 64(6):859-64. PubMed ID: 15528283
[TBL] [Abstract][Full Text] [Related]
12. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
Gladman DD; ; Sampalis JS; Illouz O; Guérette B
J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
[TBL] [Abstract][Full Text] [Related]
13. Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil.
Madland TM; Björkkjaer T; Brunborg LA; Fröyland L; Berstad A; Brun JG
J Rheumatol; 2006 Feb; 33(2):307-10. PubMed ID: 16465662
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
de Vlam K; Lories RJ
Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
[TBL] [Abstract][Full Text] [Related]
16. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study.
McHugh NJ; Balachrishnan C; Jones SM
Rheumatology (Oxford); 2003 Jun; 42(6):778-83. PubMed ID: 12730539
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices.
Gottlieb AB; Mease PJ; Mark Jackson J; Eisen D; Amy Xia H; Asare C; Stevens SR
J Dermatolog Treat; 2006; 17(5):279-87. PubMed ID: 17092858
[TBL] [Abstract][Full Text] [Related]
18. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
Heneka MT; Sastre M; Dumitrescu-Ozimek L; Hanke A; Dewachter I; Kuiperi C; O'Banion K; Klockgether T; Van Leuven F; Landreth GE
Brain; 2005 Jun; 128(Pt 6):1442-53. PubMed ID: 15817521
[TBL] [Abstract][Full Text] [Related]
19. Measurement of disease activity in psoriatic arthritis. Extended report.
Ujfalussy I; Koó E
Z Rheumatol; 2003 Feb; 62(1):60-5. PubMed ID: 12624805
[TBL] [Abstract][Full Text] [Related]
20. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.
Anandarajah AP; Schwarz EM; Totterman S; Monu J; Feng CY; Shao T; Haas-Smith SA; Ritchlin CT
Ann Rheum Dis; 2008 Mar; 67(3):296-301. PubMed ID: 17967829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]